New Data Augment the Treatment Paradigm in HR+/HER2– Breast Cancer OncLive, 10 Jul 2024 Mark Pegram, MD The utility of continued CDK4/6 inhibition, selective estrogen receptor degraders (SERDs) as monotherapy or…